Portal about health, health news.

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial

Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy.
generic viagra online

Editorial Discusses Removal Of Needle Exchange Funding Ban

A Wilmington News Journal editorial discussed the potential lifting of the ban on using federal funding for needle exchange programs. The editorial notes recent Congressional action and the restrictions in a House bill that prohibit needle exchanges to operate "within a 1,000 feet of day care centers, schools, parks, playgrounds, pools and youth centers." According to the News Journal, "This rule wipes out much of the flexibility many cities need in their fight to prevent the spread of HIV among intravenous drug users. The nation"s capital, where the rates of HIV and AIDS cases are considered epidemic, would be hit the hardest because no part of the District of Columbia would be eligible for the funding according to AIDS Action." The editorial adds, "Vans patrolling near vulnerable populations - specifically young, impressionable children - are an issue that must be addressed. But well-intentioned limits should not be allowed to hold up the rest of the program," according to the News Journal (8/1).

News of the day

MicroRNAs Help Control HIV Life Cycle

Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specific microRNAs (non-coding RNAs that interfere with gene expression) reduce HIV replication and infectivity in human T-cells. In particular, miR29 plays a key role in controlling the HIV life cycle. The study suggests that HIV may have co-opted this cellular defense mechanism to help the virus hide from the immune system and antiviral drugs. The research was published today in the journal Molecular Cell.